Evidence map›Paper›PMID 41853248›Full record

ArticleFrontiers in cell and developmental biology2026

A novel kinase inhibitor, Regorafenib, blocks EGFR-dependent signaling to repress tumour metastasis in human triple-negative breast cancers.

Ludong Zhao, Chunxin Wang, Yanzhi Wang, Meijing Liu, Hongyu Du, Xiaohui Chu, Wenqiang Yang, Wei Zhao, Guan Wang, Bo Zhang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ludong Zhao *Liaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.
Chunxin Wang *Liaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.
Yanzhi WangCollege of Basic Medical Sciences, Jinzhou Medical University, Jinzhou, Liaoning, China.
Meijing LiuLiaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.
Hongyu DuThe First Affiliated Hospital, Jinzhou Medical University, Jinzhou, Liaoning, China.
Xiaohui ChuLiaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.
Wenqiang YangLiaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.
Wei ZhaoLiaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.
Guan WangLiaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.
Bo ZhangLiaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.
Yue ZhangCollege of Basic Medical Sciences, Jinzhou Medical University, Jinzhou, Liaoning, China.
Yajing MengDepartment of Obstetrics and Gynaecology, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Hongdan LiLiaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.
Pushuai WenCollege of Basic Medical Sciences, Jinzhou Medical University, Jinzhou, Liaoning, China.
Ying LiuLiaoning Technology and Engineering Center for Tumor Immunology and Molecular Theranotics, Collaborative Innovation Center for Age-related Disease, Life Science Institute of Jinzhou Medical University, Jinzhou, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Triple-negative breast cancer (TNBC), the most aggressive subtype, poses a significant challenge as approved targeted therapies are lacking. The epidermal growth factor receptor (EGFR) is highly expressed in over 50% of TNBC cases and is implicated as a key driver in TNBC progression. Regorafenib, a small-molecule inhibitor of multiple receptor tyrosine kinases, is utilized as a second-line treatment for metastatic tumors. Methods: Bioinformatics analysis and clinical analysis of 14 breast cancer cases revealed the EGFR expression and activation in tumor tissues. Functional validation through Results: In this study, we demonstrate that Regorafenib, acting as an inhibitor of EGFR, exhibits potent anti-metastatic effects both Discussion: Our discovery of Regorafenib as a novel inhibitor of EGFR activation provides valuable insights for TNBC-specific anti-EGFR therapies targeting metastasis.

Indexed as

EGFREGFR-STAT3RegorafenibSrc-JNK/p38-YAP1 signalingtriple-negative breast cancer

Identifiers

PMID41853248
PMCPMC12992224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.